KR20150057911A - Composition for anti-imflammation, or skin whitening - Google Patents

Abstract

The present invention relates to a composition for anti-inflammation or skin whitening. A hypaconitin according to the present invention has an anti-inflammation effect by controlling generation of nitrogen oxide (NO), and a skin whitening effect by reducing total amount of melanin, thereby being used as a pharmaceutical composition, a medicine for external application, a cosmetic composition, or health food.

Description

[0001] Composition for anti-inflammation, or skin whitening [

The present invention relates to a composition for anti-inflammation or skin whitening.

On the other hand, in order to eliminate inflammation, elimination of inflammation source, reduction of vital reaction and symptoms is called anti-inflammatory. To date, substances used for antiinflammatory purposes include non-steroidal drugs such as flufenamic acid, ibuprofen, benzydamine or indomethacin, prednisolone in the steroid line, Or dexamethasone. In addition, it is known that allantoin, azene or hydrocortisone is effective for anti-inflammation. [Patent Document 1] However, these substances are limited in their use due to safety of skin, or have little effect, There is a problem that can not be expected.

In addition, it is a common desire to have white skin. The color or brightness of the skin is genetically determined by the concentration and distribution of melanin in the human skin but is also influenced by environmental or physiological conditions such as sunlight, fatigue or stress. Melanin is produced by a nonenzymatic oxidation reaction in which tyrosine, an amino acid, is catalyzed by an enzyme called tyrosinase, which is subsequently converted to dopa (DOPA) and dopaquinone. The pathway for the formation of melanin is known, but the mechanism by which the melanin synthesis induces tyrosinase is not yet elucidated.

On the other hand, commonly known whitening ingredients include substances inhibiting the activity of tyrosinase enzymes such as kojic acid or arbutin, hydroquinone, vitamin C (L-ascorbic acid) There is a plant extract [Patent Document 2]. By inhibiting the synthesis of melanin pigment, they can brighten the skin tone to realize skin whitening, and it is possible to improve skin hypercholesterolemia such as stain or freckles due to ultraviolet rays, hormones or heredity. However, when applied to skin, there is a problem that the use amount is limited due to safety problems such as irritation and redness, or the effect is insignificant, so that a practical effect can not be expected.

Therefore, it is urgently required to develop a composition having an anti-inflammatory or whitening activity that is more safe than a living body, has a stable active ingredient, and is more effective than a substance having an existing anti-inflammatory or whitening effect.

Korean Patent No. 1060634 Korean Patent Publication No. 2004-0049999

Accordingly, the inventors of the present invention confirmed that hypaconitine suppresses the production of NO (NO), exhibits an anti-inflammatory effect, and significantly reduces the total amount of melanin, thereby exhibiting a whitening effect.

Accordingly, an object of the present invention is to provide an anti-inflammatory or skin whitening composition comprising a compound represented by the following formula (1) as an active ingredient:

[Chemical Formula 1]

As means for solving the above problems,

There is provided a pharmaceutical composition for anti-inflammation or skin whitening comprising a compound represented by the following general formula (1) as an active ingredient.

 [Chemical Formula 1]

As another means for solving the above problems,

There is provided a cosmetic composition for anti-inflammation or skin whitening comprising a compound represented by the following formula (1) as an active ingredient.

[Chemical Formula 1]

Hypaconitine according to the present invention inhibits the production of nitric oxide (NO) which is involved in an inflammatory reaction and thus has an excellent anti-inflammatory effect and remarkably decreases the total amount of melanin, thereby exhibiting a whitening effect. Thus, it can be used for medicines, cosmetics or health foods .

Hereinafter, the configuration of the present invention will be described in detail.

In order for the anti-inflammatory or whitening component to exert an excellent effect when applied to actual skin, it is preferable that it exhibits high activity of anti-inflammatory or whitening activity at a low concentration and is excellent in the ability to permeate and absorb the skin. In addition, it is low in volatility so as to be able to stay for a sufficient time to exhibit an anti-inflammatory or whitening effect, and it is preferable that the composition or the active ingredient on the skin is stably maintained, is easily formulated into medicines or cosmetics, and is safe for the skin. However, among the known components, the components satisfying all of the above characteristics are not common. For example, some antiinflammatory or whitening ingredients are excellent in antiinflammatory or whitening activity even at low concentrations in vitro, but they are difficult to apply to real skin because of their ability to permeate through the skin. Other active ingredients have low hydrophilicity and are difficult to formulate into medicines or cosmetics. In addition, some antiinflammatory or whitening ingredients, when exposed to heat, light, or oxygen, may degrade the active ingredient before it is applied to the skin by degradation or transformation into other compounds.

As can be seen in the following examples, Hypaconitine has an inhibitory effect on nitric oxide production at a low concentration. Therefore, it can be used as an effective ingredient for medicines, cosmetics or health food for anti-inflammation or skin whitening.

Accordingly, the present invention provides a pharmaceutical composition for anti-inflammation or skin whitening comprising a compound represented by the following general formula (1) as an active ingredient.

[Chemical Formula 1]

The compound of formula (I) is called hypaconitine and may include all possible isomers.

The compound of formula (1) may be synthesized or a commercially available compound may be used.

The pharmaceutical composition for anti-inflammation or skin whitening of the present invention may comprise a pharmaceutically acceptable salt of the compound of formula (1).

The pharmaceutically acceptable salt of the compound of Chemical Formula 1 may be an acid addition salt formed using an organic acid or an inorganic acid, and examples of the organic acid include formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, The present invention also relates to the use of a compound selected from the group consisting of malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, gluconic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, Benzenesulfonic acid, p-toluenesulfonic acid or methanesulfonic acid-based salts. The inorganic acid includes, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid or boric acid-based salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.

The above-mentioned acid addition salts may be obtained by a) directly mixing the compound of formula 1 and an acid, or b) dissolving and mixing one of them in a solvent or a water solvent, or c) Lt; RTI ID = 0.0 > acid < / RTI > in a solvent and mixing them.

Separately, additionally saltable forms include, but are not limited to, the salts of gabapentin, gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, lysine, Aspartate and the like.

When the compound of Chemical Formula 1 of the present invention is used as a medicine, it may further contain one or more active ingredients showing the same or similar functions. For example, a known anti-inflammatory or skin whitening component. The inclusion of additional anti-inflammatory or skin whitening ingredients may further enhance the anti-inflammatory or skin whitening effects of the compositions of the present invention. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. In one embodiment of the invention, the composition is a whitening ingredient known in the art and includes a substance inhibiting tyrosinase enzyme activity such as kojic acid or arbutin, hydroquinone, vitamin C (L-Ascorbic acid), derivatives thereof, and various plant extracts. The additional component may be contained in an amount of 0.0001 wt% to 10 wt% based on the total weight of the composition. For example, from 0.0001 wt% to 1 wt%, from 0.0001 wt% to 0.1 wt%, from 0.0001 wt% to 0.001 wt%, from 0.001 wt% to 10 wt%, from 0.001 wt% 0.001 wt% or more to 0.1 wt% or less, 0.01 wt% or more to 10 wt% or less, or 0.01 wt% or more to 1 wt% or less. The content range may be adjusted according to requirements such as skin safety, ease of formulation of the compound of Formula 1, and the like.

In addition, the pharmaceutical composition for anti-inflammation or skin whitening of the present invention may further comprise a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers may contain various components such as buffer, injectable sterile water, normal saline or phosphate buffered saline, sucrose, histidine, or polysorbate.

The pharmaceutical composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, in a variety of oral or parenteral formulations upon clinical administration. In the case of formulation, , Extenders, binders, wetting agents, disintegrating agents, or surfactants.

Solid form preparations for oral administration include tablets, pills, powders, granules or capsules, which may be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin, and the like.

In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions or syrups. In addition to water or liquid paraffin, which is a simple diluent commonly used, various excipients such as wetting agents, sweetening agents, fragrances or preservatives may be included.

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations or suppositories. Non-aqueous vehicles or suspending agents include vegetable oils such as propylene glycol, polyethylene glycol or olive oil; And injectable esters such as ethyl oleate may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao paper, laurin or glycerogelatin can be used.

In the present invention, the term 'anti-inflammatory effect' refers to inhibition of inflammation. The inflammation is one of biological tissue defense responses to a certain stimulus and refers to complicated lesions involving tissue degeneration, circulatory disorders, exudates and tissue proliferation. More specifically, inflammation is part of congenital immunity and, like in other animals, human congenital immunity recognizes a pattern of cell surfaces that are specifically present in a pathogen. Phagocytes recognize cells with such surfaces as non-magnetic and attack pathogens. If pathogens break through the physical barriers of the body, an inflammatory reaction occurs. Inflammation is a nonspecific defense that creates hostile environments for microorganisms entering the wound. In the inflammatory response, white blood cells that are responsible for the early stage of immune response, when wounded or infected, enter the body to express cytokines. Therefore, the expression level of intracellular cytokine is an index of inflammatory response activation. Examples of skin diseases associated with inflammation include, but are not limited to, atopic dermatitis, psoriasis caused by psoriasis, radiation, chemicals or burns; Itching caused by acid burns, watery skin diseases, psoriasis type diseases or allergies; Inflammatory hair loss such as seborrhoeic eczema, rose acne, pemphigus pemphigus, polymorphous exudative erythema, erythema nodosum, acuminate, pharyngitis or alopecia areata; Skin T-cell lymphoma, and the like.

In the present invention, the 'whitening effect' refers to not only brightening the skin tone by inhibiting the synthesis of the melanin pigment but also improving skin hypercholesterolemia due to ultraviolet rays, hormones or heredity, such as spots or freckles.

The pharmaceutical composition of the present invention can provide an effective anti-inflammatory or whitening effect when an effective amount of the compound of Formula 1 is included. In the present invention, the term "effective amount" means the amount of a compound capable of suppressing injured inflammation or exhibiting a whitening effect. The effective amount of the compound of formula (1) contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, the method in which the compound is applied to the skin or the time on the skin. For example, when the composition is commercialized as a pharmaceutical product, the compound of Formula 1 may be contained at a higher concentration than that of a cosmetic product that is routinely applied to skin. Accordingly, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount of the compound of formula (1) 6 times a day.

The pharmaceutical compositions of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy or biological response modifiers.

The present invention can also be provided as a formulation of an anti-inflammatory or whitening external preparation for skin comprising the compound of formula (1) as an active ingredient.

When the compound of formula (1) is used as an external preparation for skin, it may further comprise at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, Such as water, an ionic emulsifier, a nonionic emulsifier, a filler, a sequestering agent, a chelating agent, a preservative, a vitamin, a blocker, a wetting agent, a necessary oil, a dye, a pigment, a hydrophilic activator, Such as any other ingredients conventionally used in the field of skin science. The components can also be introduced in amounts commonly used in the field of dermatology.

When the compound of Formula 1 is provided as an external preparation for skin, it may be a formulation such as ointments, patches, gels, creams or sprays.

The present invention can also be provided as a formulation of an anti-inflammatory or whitening cosmetic composition containing the compound of Formula 1 as an active ingredient.

When the compound of Chemical Formula 1 is used as a cosmetic, the cosmetic product containing the compound of Chemical Formula 1 as an active ingredient may be prepared in the form of a general emulsion or solubilized formulation. Lotion such as soft lotion or nutrition lotion; Lotion such as facial lotion or body lotion; Creams such as nutritional creams, moisture creams or eye creams; essence; Makeup ointment; spray; Gel; pack; Sunscreen; Makeup base; A foundation such as a liquid type, a solid type or a spray type; powder; Makeup removers such as cleansing creams, cleansing lotions, cleansing oils; Detergents such as cleansing foams, soaps, body wash, and the like.

The cosmetic composition may further contain, in addition to the compound of Formula 1, a lipid, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, , An ionic emulsifier, a nonionic emulsifier, a filler, a chelating agent, a chelating agent, a preservative, a vitamin, a blocker, a humectant, essential oil, a dye, a pigment, a hydrophilic active agent, ≪ / RTI > may be included.

In the case of a wash-off type cosmetic such as a make-up removing agent or a detergent in which the active ingredient remains on the skin in a short period of time when the compound of formula (1) is commercialized, a relatively high concentration of the compound of formula . On the other hand, in the case of a leave-on type cosmetics such as lotion, milk, cream or essence whose effective ingredient remains on the skin for a long period of time, the compound of the above formula 1 is contained at a lower concentration than that of the wash- It may be possible. In one embodiment of the present invention, although not limited thereto, the composition may contain 0.0001 wt% to 10 wt% (preferably 0.0001 wt% to 1 wt%) of the compound of Formula 1 based on the total weight of the composition . If the composition of the present invention contains less than 0.0001% by weight of the compound of formula 1, sufficient anti-inflammatory or whitening effect can not be expected. If the composition contains more than 10% by weight, This is to prevent safety problems.

The present invention also relates to an anti-inflammatory or whitening health food comprising the compound of formula (1).

The term 'health food' as used herein means a food prepared by adding the compound of formula (1) to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering or suspension, But it has the advantage that there is no side effect that can occur when a drug is taken for a long time using a food as a raw material, unlike a general medicine.

Since the health food of the present invention thus obtained can be taken on a daily basis, a high anti-inflammatory or whitening effect can be expected, which is very useful.

When the compound of Chemical Formula 1 is used as a food additive, the compound of Chemical Formula 1 may be added as it is or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in case of long-term ingestion for health and hygiene purposes, the active ingredient may be contained in an amount not exceeding the above range and there is no problem in terms of safety.

There is no particular limitation on the kind of the food. Examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, or vitamin complexes, and includes all health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as additional components such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjusting agent, Glycerin, an alcohol or a carbonating agent, and the like. In addition, the health food of the present invention may contain natural fruit juice, fruit juice drink, or pulp for the production of vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

Reference Example  One: Haifaconitine ( Hypaconitine ) Material Information

 [Chemical Formula 1]

(1?, 6 ?, 14 ?, 15 ?, 16? -Acetatebenzoate; 15-tetrol, 16,16-trimethoxy-4- (methoxymethyl) -20-methyl-18-aconitane-14; (Methoxymethyl) -20-methyl-, 8-acetate 14-benzo [epsilon] (1?, 6 ?, 14 ?, 15 ?, 16?) 1,6,16-trimethoxy-4- (methoxymethyl) -20-methyl aconitane- 8,13,14,15-tetrol 8-acetate 14-Benzoate

CAS No .: 6900-87-4

Where to buy: Sichuan Hongjie Import & Export CO., LTD

Example  1: Reduction effect of total melanin

(B-16 mouse melanoma cell) to determine the whitening effect by measuring the total amount of melanin at the cellular level (Lotan R., Lotan D. Cancer Res . 40: 3345-3350, 1980). To evaluate the toxicity of melanoma cells in rats before the experiment, whitening evaluation was performed by selecting a concentration that is not toxic.

The compound of formula (I) was added to the culture medium to give final concentrations of 5 ppm, 10 ppm, and 20 ppm, and the control group, arbutin, was added to the medium to 200 ppm, followed by treatment with B-16 melanoma cells for 3 days.

Cells were then trypsinized, detached from the culture, centrifuged, and then melanin was extracted. The removed cells were incubated with 1 ml of sodium hydroxide solution (1N concentration), boiled for 10 minutes to dissolve melanin, and the absorbance was measured at 400 nm using a spectrophotometer to measure the amount of melanin produced.

The amount of melanin was measured by the absorbance of 10 ⁶ cells per unit cell, and the total amount of melanin relative to the control group was calculated as the inhibition rate (%). The results are summarized in Table 1. The experiment was repeated three times.

Reduction of total melanin levels at the cellular level by concentration sample Total amount of melanin Inhibition rate (%) Control group (no addition) 0.234 - Control 1: Arbutin (200 ppm) 0.156 33.3 The compound of formula (1) (20 ppm) 0.068 70.9 The compound of formula (1) (10 ppm) 0.122 47.9 The compound of formula (1) (5 ppm) 0.136 41.9

As shown in the results of Table 1, the total amount of melanin in the melanoma cells of rat melanoma cells cultured at a low concentration compared to arbutin (200 ppm), which is known as a whitening substance, .

Example  2: Anti-inflammatory effect - NO  Production inhibitory effect

In order to confirm the anti-inflammatory effect and skin tear-reducing effect, the nitric oxide (NO) formation inhibition test was performed by the GRIESS method using RAW264.7 cell line (ATCC number: CRL-2278).

Specifically, RAW264.7 cells, macrophages of mice, were subcultured several times, placed in 24-well plates at 3 × 10 ⁵ per well, and cultured for 24 hours. Then, the cells were cultured in a cell culture medium containing 1% (10 mg / ml), 0.1% (1 mg / ml), 0.01% (0.1 mg / ml) and 0.001% (0.01 mg / ml) . At this time, 0.001% of L-NMMA (L-NG-Monomethylarginine), which is an inhibitor of NO production, was treated with a positive control and cultured for 30 minutes. Lipopolysaccharide (LPS) Respectively. 100 μl of the supernatant was transferred to a 96-well plate, and 100 μl of the GRIESS solution was added thereto at room temperature for 10 minutes. The absorbance at 540 nm was measured to determine the NO inhibitory effect of the compound of formula (1) Are shown in Table 2 below.

NO generation inhibitory effect sample NO production inhibition rate (%) L-NMMA (positive control, 0.001%) 44.33 Compound (1) (0.001%) 18.31 The compound of formula (1) (0.01%) 24.03 Compound (1) (0.1%) 29.12 Compound (1) (1) 35.12

As can be seen from the above Table 2, the compound of Chemical Formula 1 has a low activity but exhibits excellent activity as a natural substance when compared with L-NMMA which is a representative anti-inflammatory drug, It can act as a role and expect a synergistic effect.

Formulation example  1: Preparation of pharmaceutical preparations

1. Manufacturing of powder

0.001 g of the compound of formula (1)

Lactose 1g

The above components were mixed and packed in airtight bags to prepare powders.

2. Preparation of tablets

0.2 mg of the compound of formula (1)

100 mg of corn starch

100 mg of milk

Stearic acid  Magnesium 2 mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of capsules

0.2 mg of the compound of formula (1)

100 mg of corn starch

100 mg of milk

Stearic acid  Magnesium 2 mg

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

4. Manufacture of rings

0.003 g of the compound of formula (1)

Lactose 1.5 g

Glycerin 1 g

Xylitol  0.5 g

After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.

5. Manufacture of granules

2 mg of the compound of formula (1)

Soybean extract 50 mg

200 mg of glucose

600 mg of starch

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 캜 to form granules, which were then filled in a capsule.

Formulation example  2: Manufacture of cosmetics

1. Manufacture of softening longevity (skin lotion)

As the following composition, the number of softening times containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.

0.1% by weight of the compound of formula (1)

Beta-1,3-glucan 1.0 wt%

Butylene glycol 2.0 wt%

Propylene glycol 2.0 wt%

Carboxyvinyl polymer 0.1 wt%

0.2% by weight of phage-12 nonylphenyl ether

Polysorbate 80 0.4 wt%

Ethanol 10.0 wt%

0.1% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

2. Manufacture of nutrition lotion (milk lotion)

As in the following composition, a nutritional lotion containing the compound of the formula (1) as an active ingredient was prepared by a conventional method.

0.1% by weight of the compound of formula (1)

Beta-1,3-glucan 1.0 wt%

4.0 wt%

Polysorbate 60 1.5 wt%

1.5% by weight of sorbitan sesquioleate

0.5% by weight liquid paraffin

Caprylic / capric triglyceride 5.0 wt%

Glycerin 3.0 wt%

3.0% by weight of butylene glycol

3.0% by weight of propylene glycol

Carboxyvinyl polymer 0.1 wt%

0.2% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

3. Manufacture of nutritional cream

A nutritional cream containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.

0.2% by weight of the compound of formula (1)

Beta-1,3-glucan 5.0 wt%

Wax 10.0 wt%

Polysorbate 60 1.5 wt%

≪ tb > < tb > < tb >

0.5% by weight of sorbitan sesquioleate

Liquid paraffin 10.0 wt%

Squalane 5.0 wt%

Caprylic / capric triglyceride 5.0 wt%

Glycerin 5.0 wt%

3.0% by weight of butylene glycol

3.0% by weight of propylene glycol

0.2% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

4. Manufacture of massage cream

A massage cream containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.

0.1% by weight of the compound of formula (1)

Beta-1,3-glucan 3.0 wt%

Wax 10.0 wt%

Polysorbate 60 1.5 wt%

≪ tb > < tb > < tb >

0.8% by weight of sorbitan sesquioleate

Liquid paraffin 40.0 wt%

Squalane 5.0 wt%

Caprylic / capric triglyceride 4.0 wt%

Glycerin 5.0 wt%

3.0% by weight of butylene glycol

3.0% by weight of propylene glycol

0.2% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

5. Manufacture of pack

A pack containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.

0.2% by weight of the compound of formula (1)

Beta-1,3-glucan 1.0 wt%

Polyvinyl alcohol 13.0 wt%

0.2% by weight of sodium carboxymethylcellulose,

Glycerin 5.0 wt%

Allantoin 0.1 wt%

6.0% by weight of ethanol

0.3% by weight of phage-12 nonylphenyl ether

Polysorbate 60 0.3 wt%

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

Formulation example  3: Topical  Produce

1. Manufacture of gel

As in the following composition, a gel containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.

0.1% by weight of the compound of formula (1)

0.1% by weight of beta-1,3-glucan

0.05% by weight of sodium ethylenediaminetetraacetate

Glycerin 5.0 wt%

Carboxyvinyl polymer 0.3 wt%

5.0% by weight of ethanol

≪ tb > < tb > < tb >

Triethanolamine 0.3 wt%

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

2. Manufacture of ointment

An ointment containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.

0.5% by weight of the compound of formula (1)

Beta-1,3-glucan 10.0 wt%

Wax 10.0 wt%

Polysorbate 60 5.0 wt%

≪ tb > < tb > < tb >

0.5% by weight of sorbitan sesquioleate

Vaseline 5.0 wt%

Liquid paraffin 10.0 wt%

Squalane 5.0 wt%

SHARE BUTTER 3.0 wt%

Caprylic / capric triglyceride 5.0 wt%

Glycerin 10.0 wt%

Propylene glycol 10.2 wt%

0.2% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

3. Preparation of topical medicament (gel ointment)

A gel ointment agent containing the compound of the formula (1) as an active ingredient was prepared according to a conventional method.

0.5% by weight of the compound of formula (1)

Beta-1,3-glucan 10.0 wt%

1.5% by weight of polyacrylic acid (Carbopol 940)

5.0% by weight of isopropanol

Hexylene glycol 25.0 wt%

Triethanolamine 1.7 wt%

Deionized water to 100%

4. Preparation of topical medicines (patches)

As the following composition, a patch containing a compound of the formula (1) as an active ingredient was prepared by a conventional method.

0.5% by weight of the compound of formula (1)

Beta-1,3-glucan 3.0 wt%

Hexylene glycol 20.0 wt%

Diethylamine 0.7 wt%

1.0% by weight of polyacrylic acid (Carbopol 934P)

0.1% by weight of sodium sulfite

1.0% by weight of polyoxyethylene lauryl ether (E.O. = 9)

1.0% by weight of polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000)

Viscous paraffin oil 2.5 wt%

2.5% by weight of caprylic acid ester / capric acid ester (Cetiol LC)

Polyethylene glycol 400 3.0 wt%

Deionized water to 100%

Formulation example  4: Manufacturing of food

Foods containing the compound of formula (I) of the present invention were prepared as follows.

1. Manufacture of Flour Food

0.05 to 1.0 part by weight of the compound of Formula 1 was added to wheat flour, and a bread, a cake, a cookie, a cracker and a noodle were prepared using the mixture to prepare a health food.

2. Manufacture of dairy products

0.2 part by weight of the compound of Formula 1 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

3. Manufacturing of wire

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer. The compound of Formula 1 was concentrated under reduced pressure in a vacuum concentrator, sprayed, and dried with a hot-air drier, and the resulting dried product was pulverized to a size of 60 mesh with a pulverizer to obtain a dried powder.

The grains, seeds, and dry powder of the compound of formula (1) prepared above were blended in the following proportions relative to 100 parts by weight of the mixed powder.

(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

(1) (0.1 part by weight),

(0.5 part by weight),

Rhubarb (0.5 Weight portion )

Formulation example  5: Manufacture of beverages

1. Manufacture of health drinks

0.1 mg of the compound of formula (1)

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water  All 900 mL

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring. Then, the solution thus prepared was filtered and sterilized in a sterilized 2L-container, Lt; RTI ID = 0.0 > health < / RTI >

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

2. Manufacture of vegetable juice

1 g of the compound of formula (I) of the present invention was added to 1,000 mL of tomato or carrot juice to prepare vegetable juice for health promotion.

3. Manufacture of fruit juice

1 g of the compound of formula (1) was added to 1,000 mL of apple or grape juice to prepare fruit juice for health promotion.

Claims (4)

An antiinflammatory pharmaceutical composition comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

An anti-inflammatory cosmetic composition comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

A pharmaceutical composition for skin whitening comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

A cosmetic composition for skin whitening comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]